Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers

Targeted radiopharmaceuticals for therapeutic use deliver radionuclides directly to tumor anywhere in the body, and therefore, have renewed interest for clinical development in women with disseminated chemorefractory ovarian cancers. About two in every five women with advanced stage ovarian cancer o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunos, Charles A., Capala, Jacek, Finnigan, Shanda, Smith, Gary L., Ivy, Susan Percy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448015/
https://www.ncbi.nlm.nih.gov/pubmed/30984615
http://dx.doi.org/10.3389/fonc.2019.00180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448015/
https://www.ncbi.nlm.nih.gov/pubmed/30984615
http://dx.doi.org/10.3389/fonc.2019.00180

Ejemplares similares